$Kintara Therapeutics (KTRA.US)$ Well I think the approach i...

Well I think the approach is sound and prudent. Paying Dennis Brown as a consultant is financially sound compared to retaining him when VAL-083 is suspended. Also happy that the board is together with the shareholders in helping to cut cost by not taking the fees. Let's see what the shorts make of this news.